April 2026 in “International Journal of Impotence Research” This review outlines the major health consequences of anabolic-androgenic steroid abuse, with a focus on sexual and reproductive issues, and suggests management prioritizes cessation and relapse prevention due to lack of robust randomized trials.
This narrative review concludes that long-term randomized controlled trials are needed to establish clear guidelines for testosterone therapy in women, given the lack of FDA-approved formulations and the variable quality of current treatments.
March 2026 in “INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT” This study suggests that herbal hair dyes, using natural pigments, may provide a safer, eco-friendly alternative to traditional synthetic dyes, although their effectiveness depends on application technique and botanical purity.
March 2026 in “Pharmaceuticals” This study found that the type of reporter significantly influences the detection of cancer therapy-induced alopecia signals, highlighting differences in signal amplification between patients and healthcare professionals.
March 2026 in “The Journal of Sexual Medicine” In this study, older women aged 70 and above, treated for sexual dysfunction using carefully monitored hormone therapy, reported improvements in sexual function and symptom relief, with no incidences of cancer or thromboembolic events, though some experienced breast tenderness and hair changes.
February 2026 in “Preprints.org” This study analyzed data from the FDA Adverse Event Reporting System to evaluate cancer therapy–induced alopecia, finding that reporter type significantly affects signal detection, with docetaxel showing the highest disproportionate association overall, and vismodegib ranking highest among healthcare professional reports.
October 2025 in “Environment International” This study reports that prenatal and prepubertal exposure to organochlorine compounds and perfluoroalkyl substances may affect pubertal development at age 12, with observed changes in development patterns in both girls and boys, highlighting the need for further research.
October 2025 in “Journal of the Endocrine Society” In this case report, a transgender woman with refractory epilepsy began estrogen therapy for gender-affirming purposes, experiencing stable epilepsy and reduced gender dysphoria through ongoing multidisciplinary care, highlighting the importance of careful management for similar patients.
April 2025 in “International Journal For Multidisciplinary Research” This case report details the investigation and management of a 3-year-old girl with precocious pseudopuberty due to a Sertoli-Leydig cell tumor, highlighting the importance of early recognition and accurate diagnosis for effective treatment and prognosis.
August 2024 in “Research Square (Research Square)” This study found that women taking 5α-reductase inhibitors (5aRI) for alopecia had a lower risk of breast cancer compared to those not using these medications, with no increased risk of developing ovarian or endometrial cancer.
June 2024 in “British Journal of Dermatology” This narrative focuses on the experiences of two women with permanent chemotherapy-induced alopecia, highlighting the severe psychological and social impact along with dissatisfaction over pre-treatment information about hair loss, which they initially believed to be temporary.
In this study, researchers developed a computational method called iEdgePathDDA that prioritizes anticancer drug candidates by analyzing changes in gene interactions, demonstrating superior performance compared to existing methods across colorectal, breast, and lung cancer datasets.
February 2024 in “Hormones” This study surveyed individuals seeking estrogen-based gender-affirming hormone therapy, revealing that improving life satisfaction and femininity are top treatment goals, and highlighting the need for trials aligned with community priorities.
January 2024 in “International Research Journal of Modernization in Engineering Technology and Science” In this study, researchers examined common chemotherapy side effects among 100 Pakistani cancer patients and explored the potential side effect reduction through hunger-based differential chemotherapy. They found widespread adverse reactions, with only 18% willing to fast for over 24 hours.
This study introduces Kalya Research, an AI-driven tool designed to identify and categorize literature on complementary and alternative medicines, showing its effectiveness compared to Medline in finding relevant alopecia research within the context of breast cancer patients.
This study synthesized new heterocyclic steroid derivatives and reported their promising antiproliferative activity against breast and prostate cancer cell lines, highlighting selectivity and impact on signaling pathways even in cells resistant to certain treatments.
June 2023 in “Journal of Ayurvedic and herbal medicine” This review article highlights the potential health benefits and pharmaceutical components of pumpkin seeds, which contain proteins, antioxidants, and essential nutrients, and discusses their traditional medicinal uses and emerging applications in the food industry.
June 2023 in “The journal of sexual medicine” This case report describes a 10-year multidisciplinary treatment of a transgender woman in Slovenia, reporting a successful medical and social transition with stable emotional health, abstinence from alcohol, and no regrets following her transition.
November 2022 in “Journal of the Endocrine Society” This case study reports a rare instance of an estradiol-secreting adrenocortical carcinoma in a 58-year-old male, causing feminization and Marie-Antoinette syndrome, with potential paraneoplastic aortitis.
May 2022 in “Annals of Oncology” This study found that photobiomodulation may accelerate hair regrowth one month after chemotherapy in breast cancer patients, but no significant differences were observed at two and three months post-therapy.
March 2022 in “Proceeding Of Sari Mulia University Midwifery National Seminars” This review suggests that garlic contains substances which may complement breast cancer treatment, but it reports no new experimental results.
August 2020 in “Nigerian journal of paediatrics” This case report describes a 24-month-old girl from Nigeria with idiopathic precocious puberty, emphasizing the financial barriers to necessary treatment in developing countries.
May 2018 in “Indian Journal of Plastic Surgery” The book is a detailed guide for plastic surgeons with clear explanations and is recommended for both new and experienced practitioners.
January 2018 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” This study found that chemotherapy for breast cancer initially reduced hair density and anagen hair rate, which then returned to baseline or higher, whereas tamoxifen did not significantly affect hair growth.
December 2017 in “Revista da Sociedade Portuguesa de Dermatologia e Venereologia” This report describes a case where a woman developed permanent alopecia after chemotherapy with taxanes for breast cancer, and she showed favorable response to 6 months of minoxidil topical treatment.
This chapter reviews the presence and roles of stem cells in various body systems, focusing on their lifelong function in animals and humans, and reports no new experimental findings.
January 2015 in “Side effects of drugs annual” This review discusses various sex hormones and related compounds, including estrogens and anabolic steroids, but reports no new findings; it highlights existing literature from 2014 regarding their use and effects.
January 2014 in “Plastic and Aesthetic Research” This article discusses the evolutionary nature of the field of plastic surgery and introduces the new journal, Plastic and Aesthetic Research, without presenting new research findings.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.